Genmab A/S (NASDAQ:GMAB) Shows Under-Valuation Amid Near-Term Bearish Momentum

Strong cash generation and an under-valued WMDST appraisal contrast with compressed profitability and weakening short-term momentum; technical indicators signal elevated downside risk over the coming weeks. Fundamental cash flow and a sizable pipeline sustain valuation support despite mixed operational trends.